NO943388L - Selektiv forandring av antistoff-immunogenisitet - Google Patents

Selektiv forandring av antistoff-immunogenisitet

Info

Publication number
NO943388L
NO943388L NO943388A NO943388A NO943388L NO 943388 L NO943388 L NO 943388L NO 943388 A NO943388 A NO 943388A NO 943388 A NO943388 A NO 943388A NO 943388 L NO943388 L NO 943388L
Authority
NO
Norway
Prior art keywords
idiotype
immunogenicity
response
antibody
selective change
Prior art date
Application number
NO943388A
Other languages
English (en)
Norwegian (no)
Other versions
NO943388D0 (no
Inventor
Thomas R Sykes
Mark Reddish
Richard P Baum
Antoine A Noujaim
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of NO943388D0 publication Critical patent/NO943388D0/no
Publication of NO943388L publication Critical patent/NO943388L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO943388A 1992-03-18 1994-09-12 Selektiv forandring av antistoff-immunogenisitet NO943388L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85360592A 1992-03-18 1992-03-18
PCT/CA1993/000110 WO1993018792A1 (fr) 1992-03-18 1993-03-18 Alteration selective de l'immunogenicite des anticorps

Publications (2)

Publication Number Publication Date
NO943388D0 NO943388D0 (no) 1994-09-12
NO943388L true NO943388L (no) 1994-11-18

Family

ID=25316485

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943388A NO943388L (no) 1992-03-18 1994-09-12 Selektiv forandring av antistoff-immunogenisitet

Country Status (7)

Country Link
EP (1) EP0631507A1 (fr)
JP (1) JPH07504668A (fr)
AU (1) AU3881593A (fr)
CA (1) CA2131621A1 (fr)
FI (1) FI944314A0 (fr)
NO (1) NO943388L (fr)
WO (1) WO1993018792A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
JP2002504154A (ja) * 1997-06-17 2002-02-05 アルタレックス コーポレイション 治療用組成物および治療方法
WO2011075861A1 (fr) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Procédé pour faire baisser l'immunogénicité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies

Also Published As

Publication number Publication date
NO943388D0 (no) 1994-09-12
JPH07504668A (ja) 1995-05-25
AU3881593A (en) 1993-10-21
CA2131621A1 (fr) 1993-09-30
EP0631507A1 (fr) 1995-01-04
FI944314A (fi) 1994-09-16
FI944314A0 (fi) 1994-09-16
WO1993018792A1 (fr) 1993-09-30

Similar Documents

Publication Publication Date Title
FI934861A0 (fi) Foerfarande foer framstaellning av 3a-hydroxi, 3b-substituerade pregnaner
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
MXPA03007853A (es) Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
EP0675904A4 (fr) Anticorps monoclonaux neutralisateurs humains contre le virus de l'immunodeficience humaine.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DK517380A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
NO933179L (no) Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE59914538D1 (de) Tetravalente Antikörperkonstrukte
ES2136760T3 (es) Produccion de inmunoglobulinas humanizadas y polinucleotidos correspondientes.
SG6586G (en) Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic composi
HUP0301235A2 (hu) Központi idegrendszeri betegségek kezelése glatiramer-acetát elleni antitestekkel
SE7803280L (sv) Konstruktionselementsats for tillverkning av variabla, berande stommar
NO964013D0 (no) Monoklonale antistoffer som gjenkjenner TIE-reseptor og deres anvendelse
DK517280A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
NO943388L (no) Selektiv forandring av antistoff-immunogenisitet
FI895389A0 (fi) Foerfarande foer framstaellning av 3,5 -dimetyl-4-metoxipyridinderivat samt ny mellanprodukt haerfoer.
BR9708843B1 (pt) mÉtodos de diagnàstico de mau funcionamento de malhas de controle.
DK0476226T3 (da) Monoklonalt antistof mod humant IgE
MX9305920A (es) Anticuerpos monoclonales reconfigurados, contra un isotipo de inmunoglobulina.
KR900009595A (ko) 2-클로로-5-클로로메틸피리딘의 제조방법
JPS5435870A (en) Exhaust gas denitration method
SE7801930L (sv) Sett att framstella 1,3,5-triazin-2,6-dioner
NL7807723A (nl) Werkwijze voor de bereiding van synthesegassen door partiele oxydatie.
NO952157L (no) Fremgangsmåte ved fremstilling av avrivningsslokk, samt avrivningslokk fremstilt ved denne fremgangsmåten